

One Time Therapy For Treating Nasal Allergy Symptoms

Arrinex, Inc. is a clinical stage start up located in Redwood City, CA. The company has pioneered a potential curative therapy for chronic rhinitis through a single office based procedure. This short procedure is performed under local anesthesia and requires no incision. There are 24 million patients with chronic nasal allergies in the U.S., 2.5 million of which are refractory and represent the initial target market for Arrinex. Arrinex's approach for treating nasal allergy symptoms is supported by published clinical and scientific literature with potential success rate of up to 90%. While improving quality of life of this group of patients, Arrinex's procedure introduces a significant cost saving solution to them as well.

COMPANY HIGHLIGHTS:

PRODUCT /IP:

- Product design completed
- Single use disposable device
- Solid IP

REGULATORY/CLINICAL

- 510k path with no clinical data requirement
- 510K to be cleared by Q1 2016
- 30 patient pilot study underway in 3 sites in the U.S.

MARKETING:

- First mover in a large market
- Office based procedure
- Patients largely dissatisfied with drugs

FINANCING:

- Raising \$5M, Series "A" to
 - ✓ Obtain 510K clearance
 - ✓ Complete clinical study
 - ✓ Initial market release

INVESTMENT HIGHLIGHTS:

- Low burn/low capital requirement
- High gross margin: >90%
- Short time to market (2016)
- Strong interest from physicians and patients
- Experienced management team

MANAGEMENT TEAM:

Vahid Saadat: President & CEO
Mojgan Saadat: Co-Founder
Kristine Tatsutani, Ph.D: Reg./Clin.
Bryant Lin, M.D.: CMO
Contact: Vahid Saadat
C: 408-802-2052
Vahid@arrinex.com

CLINICAL ADVISORS:

Peter Hwang, M.D., President Elect, ARS, Rhinology Chair, Stanford U.
William Bolger, M.D., Chief of Rhinology, Mayo, Acclarent advisor
Richard Goode, M.D., Professor Emeritus, Past ENT Chair, Stanford University
Lionel Nelson, M.D., Private Practitioner, San Jose, CA
Marshall Strome, M.D., Former Department Chair, Cleveland Clinic